PASI score: combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72(maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck [h], arms [u],trunk [t],legs [l]);each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90 to 100 percent involvement),severity estimated by clinical signs: erythema(E),infiltration(I),scaling(S);5 point scale:0(no involvement) to 4(very marked involvement).Final PASI score = 0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl),where head:0.1;upper limbs:0.2;trunk:0.3;lower limbs:0.4. Percentage of participants with at least 50% improvement in total PASI score at Week 8 relative to baseline total PASI score was reported and 95% confidence interval was calculated using Clopper-Pearson (exact) method.

PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), infiltration (I), and scaling (S) across all psoriatic lesions. The severity rating scores (erythema: 0= no evidence of erythema to 4= dark, deep red; infiltration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S = total) and the average (total score divided by 3) was calculated. The average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was ranging from: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher scores indicated more severity.

Hematology (decrease of greater than or equal to [>=] 5% hematocrit, hemoglobin >=20 gram per liter [g/L]; white blood cell less than [<] 3.0*10^9/L; neutrophil <1.5*10^9/L; platelet <100*10^9 /L; eosinophil greater than [>] 0.5*10^9/L); coagulation (prothrombin, partial thromboplastin time >1.5*upper limit of normal [ULN]); chemistry (above ULN or below lower limit of normal [LLN] for [sodium >5 millimole per liter {mmol/L}; potassium >0.5 mmol/L; glucose {fasting} >0.83 mmol/L; glucose {non fasting} >5.0 mmol/L; phosphorus >0.162 mmol/L]; creatinine >1.36*ULN; blood urea nitrogen/urea >1.5*ULN; creatine kinase >3*ULN; change from baseline in [calcium >=0.25 mmol/L; magnesium >=0.21 mmol/L; total protein >=20 g/L; albumin >=10 g/L; uric acid >0.119 mmol/L]; fasting [cholesterol >7.77 mmol/L; triglyceride >3.39 mmol/L]); liver test (alanine amino [A] transferase [T], aspartate AT, total bilirubin >2*ULN; alkaline phosphatase >1.5*ULN; gamma glutamyl T, lactate dehydrogenase >3*ULN).

Sitting and supine systolic blood pressure (BP): increase of >=20 millimeter mercury (mm Hg) from baseline value and >=160 mm Hg; decrease of >=20 mm Hg from baseline value and less than or equal to (<=) 90 mm Hg. Diastolic BP: increase of >=15 mm Hg from baseline value and >=100 mm Hg; decrease of >=15 mm Hg from baseline value and <=50 mm Hg. Heart rate: increase of >15 beats per minute (bpm) from baseline value and >=120 bpm; decrease of >15 bpm from baseline value and <=45 bpm. Orthostatic (supine to standing): 1) systolic BP: decrease of >=20 mm Hg from supine value; 2) diastolic BP: decrease of >=20 mm Hg from supine value; 3) heart rate: increase of >=30 bpm from supine value. Oral temperature <35 degree Celsius or >38.3 degree Celsius. Respiratory rate <10 breaths per minute; >25 breaths per minute. Weight >=7% increase or decrease from baseline value.

Criteria for abnormality of potential clinical importance: PR interval: change of >=20 milliseconds (msec) from baseline value and >=220 msec; QRS interval: >=120 msec; corrected QT (QTc) interval (men): >450 msec and QTc interval (women): >470 msec.

t1/2 was the time measured for the serum concentration of ILV-095 to decrease by one half.

AUCinf was calculated as AUClast + (Clast/kel), where AUClast was area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (Clast) and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

AUClast was the area under the serum concentration versus time curve from time zero to the time of the last quantifiable concentration (Clast).

Clearance was a quantitative measure of the rate at which ILV-095 was removed from the blood (rate at which ILV-095 was metabolized or eliminated by normal biological processes).

Apparent volume of distribution was defined as the theoretical volume in which the total amount of ILV-095 was needed to be uniformly distributed to produce the desired serum concentration of ILV-095.

Serum amyloid-A (SAA) is a low molecular weight acute phase protein. Serum samples were analyzed for SAA concentrations using solid phase sandwich enzyme-linked immunosorbent assay. The limit of detection (LOD) for SAA assay was 0.21 ng/mL.

Interleukin: group of naturally occurring proteins that are particularly important in stimulating immune responses such as inflammation. Plasma samples were analyzed for IL-6 concentrations using high sensitive enzyme-linked immunosorbent assay. The limit of detection for IL-6 assay was 0.00002 ng/mL.

Interleukin: group of naturally occurring proteins that are particularly important in stimulating immune responses such as inflammation. Plasma samples were analyzed for IL-22 concentrations using highly sensitive enzyme-linked immunosorbent assay. The lower limit of quantification for IL-22 assay was 0.34 pg/mL.

CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation. Serum samples were analyzed for CRP concentrations using nephelometry.

The serum samples were analyzed for anti-drug antibodies of ILV-095 by a validated electrochemiluminescence assay and participants with positive anti-drug antibodies were reported in this outcome measure.

Injection site reactions included following symptoms: injection site itching, injection site redness, injection-site swelling, injection site pain, injection site ulceration, requirement for plastic surgery associated with an injection.

Participants received single dose of placebo matching to ILV-095 subcutaneously on Day 1 and were followed up to Week 16.

Total of all reporting groups

PASI score: combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72(maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck [h], arms [u],trunk [t],legs [l]);each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90 to 100 percent involvement),severity estimated by clinical signs: erythema(E),infiltration(I),scaling(S);5 point scale:0(no involvement) to 4(very marked involvement).Final PASI score = 0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl),where head:0.1;upper limbs:0.2;trunk:0.3;lower limbs:0.4. Percentage of participants with at least 50% improvement in total PASI score at Week 4 relative to baseline total PASI score was reported and 95% confidence interval was calculated using Clopper-Pearson (exact) method.

ITT population included all randomly assigned participants who took at least 1 dose of study medication and had at least 1 clinical activity measurement (PASI score). Here, "N" signifies those participants who were evaluable for this measure.

PASI score: combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72(maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck [h], arms [u],trunk [t],legs [l]);each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90 to 100 percent involvement),severity estimated by clinical signs: erythema(E),infiltration(I),scaling(S);5 point scale:0(no involvement) to 4(very marked involvement).Final PASI score = 0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl),where head:0.1;upper limbs:0.2;trunk:0.3;lower limbs:0.4. Percentage of participants with at least 50% improvement in total PASI score at Week 6 relative to baseline total PASI score was reported and 95% confidence interval was calculated using Clopper-Pearson (exact) method.

ITT population included all randomly assigned participants who took at least 1 dose of study medication and had at least 1 clinical activity measurement (PASI score). Here, "N" signifies those participants who were evaluable for this measure.

PASI score: combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72(maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck [h], arms [u],trunk [t],legs [l]);each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90 to 100 percent involvement),severity estimated by clinical signs: erythema(E),infiltration(I),scaling(S);5 point scale:0(no involvement) to 4(very marked involvement).Final PASI score = 0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl),where head:0.1;upper limbs:0.2;trunk:0.3;lower limbs:0.4. Percentage of participants with at least 50% improvement in total PASI score at Week 8 relative to baseline total PASI score was reported and 95% confidence interval was calculated using Clopper-Pearson (exact) method.

ITT population included all randomly assigned participants who took at least 1 dose of study medication and had at least 1 clinical activity measurement (PASI score). Here, "N" signifies those participants who were evaluable for this measure.

Each lesion was evaluated for 3 components: erythema, plaque elevation, and scaling. Physician rated each component using the following scale: 0= none, 1= mild, 2= moderate, 3= severe and 4= very severe, where higher scores indicated higher lesion severity. TLS was calculated as the sum of the 3 individual components and TLS total score ranged from 0 (no disease) to 12 (maximal disease severity), where higher scores indicated more severity.

ITT population included all randomly assigned participants who took at least 1 dose of study medication and had at least 1 clinical activity measurement (PASI score). Here, "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively.

PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), infiltration (I), and scaling (S) across all psoriatic lesions. The severity rating scores (erythema: 0= no evidence of erythema to 4= dark, deep red; infiltration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S = total) and the average (total score divided by 3) was calculated. The average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was ranging from: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher scores indicated more severity.

ITT population included all randomly assigned participants who took at least 1 dose of study medication and had at least 1 clinical activity measurement (PASI score). Here, "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively.

Hematology (decrease of greater than or equal to [>=] 5% hematocrit, hemoglobin >=20 gram per liter [g/L]; white blood cell less than [<] 3.0*10^9/L; neutrophil <1.5*10^9/L; platelet <100*10^9 /L; eosinophil greater than [>] 0.5*10^9/L); coagulation (prothrombin, partial thromboplastin time >1.5*upper limit of normal [ULN]); chemistry (above ULN or below lower limit of normal [LLN] for [sodium >5 millimole per liter {mmol/L}; potassium >0.5 mmol/L; glucose {fasting} >0.83 mmol/L; glucose {non fasting} >5.0 mmol/L; phosphorus >0.162 mmol/L]; creatinine >1.36*ULN; blood urea nitrogen/urea >1.5*ULN; creatine kinase >3*ULN; change from baseline in [calcium >=0.25 mmol/L; magnesium >=0.21 mmol/L; total protein >=20 g/L; albumin >=10 g/L; uric acid >0.119 mmol/L]; fasting [cholesterol >7.77 mmol/L; triglyceride >3.39 mmol/L]); liver test (alanine amino [A] transferase [T], aspartate AT, total bilirubin >2*ULN; alkaline phosphatase >1.5*ULN; gamma glutamyl T, lactate dehydrogenase >3*ULN).

Safety population included all randomly assigned participants who took at least 1 dose of study medication.

Sitting and supine systolic blood pressure (BP): increase of >=20 millimeter mercury (mm Hg) from baseline value and >=160 mm Hg; decrease of >=20 mm Hg from baseline value and less than or equal to (<=) 90 mm Hg. Diastolic BP: increase of >=15 mm Hg from baseline value and >=100 mm Hg; decrease of >=15 mm Hg from baseline value and <=50 mm Hg. Heart rate: increase of >15 beats per minute (bpm) from baseline value and >=120 bpm; decrease of >15 bpm from baseline value and <=45 bpm. Orthostatic (supine to standing): 1) systolic BP: decrease of >=20 mm Hg from supine value; 2) diastolic BP: decrease of >=20 mm Hg from supine value; 3) heart rate: increase of >=30 bpm from supine value. Oral temperature <35 degree Celsius or >38.3 degree Celsius. Respiratory rate <10 breaths per minute; >25 breaths per minute. Weight >=7% increase or decrease from baseline value.

Safety population included all randomly assigned participants who took at least 1 dose of study medication.

Criteria for abnormality of potential clinical importance: PR interval: change of >=20 milliseconds (msec) from baseline value and >=220 msec; QRS interval: >=120 msec; corrected QT (QTc) interval (men): >450 msec and QTc interval (women): >470 msec.

Safety population included all randomly assigned participants who took at least 1 dose of study medication.

Pharmacokinetic (PK) parameter analysis population included all randomly assigned participants who took at least 1 dose of ILV-095 and had at least 1 of the PK parameters of interest.

PK parameter analysis population included all randomly assigned participants who took at least 1 dose of ILV-095 and had at least 1 of the PK parameters of interest.

t1/2 was the time measured for the serum concentration of ILV-095 to decrease by one half.

PK parameter analysis population included all randomly assigned participants who took at least 1 dose of ILV-095 and had at least 1 of the PK parameters of interest. Here, "N" signifies number of participants who were evaluable for this measure.

AUCinf was calculated as AUClast + (Clast/kel), where AUClast was area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (Clast) and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

PK parameter analysis population included all randomly assigned participants who took at least 1 dose of ILV-095 and had at least 1 of the PK parameters of interest. Here, "N" signifies number of participants who were evaluable for this measure.

AUClast was the area under the serum concentration versus time curve from time zero to the time of the last quantifiable concentration (Clast).

PK parameter analysis population included all randomly assigned participants who took at least 1 dose of ILV-095 and had at least 1 of the PK parameters of interest.

Clearance was a quantitative measure of the rate at which ILV-095 was removed from the blood (rate at which ILV-095 was metabolized or eliminated by normal biological processes).

PK parameter analysis population included all randomly assigned participants who took at least 1 dose of ILV-095 and had at least 1 of the PK parameters of interest. Here, "N" signifies number of participants who were evaluable for this measure.

Apparent volume of distribution was defined as the theoretical volume in which the total amount of ILV-095 was needed to be uniformly distributed to produce the desired serum concentration of ILV-095.

PK parameter analysis population included all randomly assigned participants who took at least 1 dose of ILV-095 and had at least 1 of the PK parameters of interest. Here, "N" signifies number of participants who were evaluable for this measure.

Serum amyloid-A (SAA) is a low molecular weight acute phase protein. Serum samples were analyzed for SAA concentrations using solid phase sandwich enzyme-linked immunosorbent assay. The limit of detection (LOD) for SAA assay was 0.21 ng/mL.

Safety population included all randomly assigned participants who took at least 1 dose of study medication. Here, "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively.

Interleukin: group of naturally occurring proteins that are particularly important in stimulating immune responses such as inflammation. Plasma samples were analyzed for IL-6 concentrations using high sensitive enzyme-linked immunosorbent assay. The limit of detection for IL-6 assay was 0.00002 ng/mL.

Safety population included all randomly assigned participants who took at least 1 dose of study medication. Here, "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively.

Interleukin: group of naturally occurring proteins that are particularly important in stimulating immune responses such as inflammation. Plasma samples were analyzed for IL-22 concentrations using highly sensitive enzyme-linked immunosorbent assay. The lower limit of quantification for IL-22 assay was 0.34 pg/mL.

Safety population included all randomly assigned participants who took at least 1 dose of study medication. Here, "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively.

CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation. Serum samples were analyzed for CRP concentrations using nephelometry.

Safety population included all randomly assigned participants who took at least 1 dose of study medication. Here, "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively.

The serum samples were analyzed for anti-drug antibodies of ILV-095 by a validated electrochemiluminescence assay and participants with positive anti-drug antibodies were reported in this outcome measure.

Safety population included all randomly assigned participants who took at least 1 dose of study medication.

Injection site reactions included following symptoms: injection site itching, injection site redness, injection-site swelling, injection site pain, injection site ulceration, requirement for plastic surgery associated with an injection.

Safety population included all randomly assigned participants who took at least 1 dose of study medication.

Participants received single dose of ILV-095 300 mg subcutaneously on Day 1 and were followed up to Week 16.

Participants received single dose of placebo matching to ILV-095 subcutaneously on Day 1 and were followed up to Week 16.